Genetic and epigenetic aspects of breast cancer progression and therapy

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1071-1077

  Byler, Shannon ^a   Goldgar, Sarah ^a   Heerboth, Sarah ^a   Leary, Meghan ^a   Housman, Genevieve ^a,b   Moulton, Kimberly ^a   Sarkar, Sibaji ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Breast cancer progression; Cancer; Cancer progenitor cells; Combination therapy; De methylation; Drug resistance; Epigenetics; Epithelial mesenchymal transition (EMT); Gene copy number; Histone deacetylase inhibitors; Histone modification; Metastasis; Methylation; Mutation; Oncogene; Review; Therapeutics; Tumor suppressor genes

Indexed keywords

BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR;

BREAST CANCER; BREAST CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; COPY NUMBER VARIATION; DNA METHYLATION; ENZYME MECHANISM; EPIGENETICS; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC TRAIT; GENETIC VARIABILITY; GENETICS; HISTONE ACETYLATION; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; STEM CELL; TRANSCRIPTION REGULATION; TUMOR GENE; ANIMAL; BREAST CANCER PROGRESSION; BREAST TUMOR; CANCER PROGENITOR CELLS; DE-METHYLATION; DISEASE COURSE; DRUG RESISTANCE; EPITHELIAL-MESENCHYMAL TRANSITION (EMT); FEMALE; GENE DOSAGE; GENETIC EPIGENESIS; GENOMICS; HISTONE MODIFICATION; METHYLATION; MUTATION; NEOPLASM; ONCOGENE; PATHOLOGY; PROGNOSIS; THERAPY; TUMOR SUPPRESSOR GENE;

BREAST CANCER; BREAST CANCER PROGRESSION; CANCER; CANCER PROGENITOR CELLS; COMBINATION THERAPY; DE-METHYLATION; DRUG RESISTANCE; EPIGENETICS; EPITHELIAL-MESENCHYMAL TRANSITION (EMT); GENE COPY NUMBER; HISTONE DEACETYLASE INHIBITORS; HISTONE MODIFICATION; METASTASIS; METHYLATION; MUTATION; ONCOGENE; REVIEW; THERAPEUTICS; TUMOR SUPPRESSOR GENES;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; GENOMICS; HUMANS; PROGNOSIS;

EID: 84899696221     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Polyak K: Heterogeneity in breast cancer. J Clin Invest 121(10): 3786-3788, 2011.
2. Viale G: The current state of breast cancer classification. Ann Oncol 23: 207-210, 2012.
3. Hsiao YH, Chou MC, Fowler C, Mason JT and Man Y: Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer 1: 6-13, 2010.
4. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70, 2012.
5. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Matin S, Varela I, Bignell GR, Yates LR, Papaemmanuli E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Wai Lau K, McLauren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A, OSBREAC, Lee MTM, Shen C, Tee BTK, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin S, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SAJR, Salomon AV, Børresen- Dale A, Richardson AL, Campbell PJ, Futreal PA and Stratton MR: The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403): 400-404, 2012.
6. Curtis C, Shah SP, Chin S, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pindler S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale A, Brenton JD, Tavaré S, Caldas C and Aparicio S: The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486(7403): 346-352, 2012.
7. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavaré S, Deloukas P and Dermitzakis ET: Genome-wide associations of gene expression variation in humans. PLoS Genet 1(6): e78, 2005.
8. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Camiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M and Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16): 7065-7070, 2005.
9. Volinia S, Galasso M, Elena Sana M, Wise TF, Palatini J, Huebner K and Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci 109: 3024-3029, 2012.
10. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM and Ellis IO: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9): 3802-3809, 2009.
11. Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD and Jeddeloh JA: Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS ONE 2(12): e1314, 2007.
12. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB and Chambers AF: Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 10(4): R62, 2008.
13. Huang Y, Nayak S, Jankowitz R, Davidson NE and Oesterreich S: Epigenetics in breast cancer: what's new?. Breast Cancer Res 13(6): 225, 2011.
14. Radpour R, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus M, Bitzer J, Lefkovits I, Staedtler F and Zhong XY: Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS ONE 6(11): e27355, 2011.
15. Mataga MA, Rosenthal S, Heerboth S, Devalapalli A, Kokolus S, Evans LR, Longacre M, Houseman G and Sarkar S: Antibreast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res 32: 2523-2529, 2012.
16. Yu U, Fujii S, Yuan L, Luo RZ, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Jr. and Ann N: Epigenetic regulation of ARHI in breast and ovarian cancer cells. NY Acad Sci 983: 268-277, 2003.
17. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60(24): 6370-6394, 2000.
18. Gore SD: Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw 4(1): 83-90, 2006.
19. Connolly RM, Jankowitz RC, Andreopoulou E, Allred JB, Jeter SC, Zorzi J, Adam BM, Espinoza-Delagado I, Baylin SB, Zahnow CA, Ahuja N, Davidson NE and Stearns V: A phase 2 study investigating the safety, efficacy, and surrogate biomarkers or response of 5-azacitidine (5-AZA) and entinostat (MS-275) in patients with advanced breast cancer. Cancer Res 71(24 Suppl 3): Abstract 4666, 2011.
20. Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz-Hernández E, Revillia-Vásquez A, Chávez-Blanco A, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Bargallo E, Villareal P, Ramírez T, Vela T, Candelaria M, Camargo MF, Robles E and Dueñas-González A: A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 1(1): e98, 2006.
21. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE and Garraway LA: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504(7478): 138-142, 2013.
22. Hanahan D and Weinberg A: Hallmarks of cancer: the next generation. Cell 144(5): 646-674, 2011.
23. Vogelstein B and Kinzler K: The multistep nature of cancer. Trends Genet 9(4): 138-141, 1993.
24. Sarkar S, Goldgar S, Byler S, Rosenthal S and Heerboth S: Demethylation and reexpression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5(1): 87-94, 2013.
25. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S and Longacre M: Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14(10): 21087-21113, 2013.
26. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Mylkebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ and Flanagan AM: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45(12): 1479-1482, 2013.